CORE--ADHERENCE TO HIV MEDICATION

艾滋病毒感染的治疗已经从根本上改变了使用 包括蛋白酶抑制剂的联合抗逆转录病毒化疗。 这些药物与逆转录酶抑制剂组合产生 血浆病毒RNA显著下降，CD/4计数增加， 改善临床结果。该疗法具有较长的前景 长期生存甚至疾病根除。同时，如果这些 药物服用量不足或如果方案给药 不规则，治疗益处丧失，抗病毒耐药性 发展起来的蛋白酶抑制剂需要严格的给药方案，大多数 通常添加到已经复杂的药物治疗方案中。而且这些 药物引起麻烦的副作用，并有大量的药物 交互.服用这些药物的患者通常在功能上 健康状况不佳，可能会有认知障碍。这些 这些因素使得艾滋病的成功治疗不再是一个 有效的药物治疗的可用性，并且更依赖于 患者随时间坚持复杂药物治疗方案的能力。 然而，衡量抗逆转录病毒治疗依从性的严格方法 药物并不广泛可用，大多数临床试验都采用了 最低限度的药物依从性评价（如果有的话）。 药物依从性核心是验证基于访谈的方法， 根据新开发的项目和ACTG中完成的工作来衡量遵守情况 和HCSUS研究。这些仪器测量病人对工作的坚持程度 在加州大学洛杉矶分校的艾滋病毒临床试验和队列研究，以（1）确定 测量药物依从性的机会，（2）提供和定制 将其纳入现有和计划的研究。（三）、 协助设计数据收集和分析战略， 依从性和与依从性相关的因素，以及（4）先前适应 适用于新人群（如儿科）的经验证仪器，以及 临床环境。此外，药物依从性核心将发挥作用 与临床试验研究者一起制定干预措施， 坚持并衡量这些干预措施的效果。此外，本发明还提供了一种方法， 与行为坚持招聘和保留核心，这个核心 将创建连贯的医疗和行为评估模块， 加州大学洛杉矶分校的研究人员。两个核心将构成健康 CFAR的行为和外联方案。

The treatment of HIV infection has been radically altered by the use of combination anti-retroviral chemotherapy including protease inhibitors. These agents in combination with reverse transcriptase inhibitors produce profound declines in plasma viral RNA, increases in CD/4 counts and improved clinical outcomes. This therapy provides the prospect for long term survival and even disease eradication. At the same time, if these medications are taken in inadequate amount or if the regimen dosing is irregular, the therapeutic benefit is lost and antiviral resistance develops. Protease inhibitors require rigorous dosing schedules, most commonly added to already complex medications regimens. Furthermore, these medications cause trouble side effects and have substantial drug interactions. The patients taking these medications often are functionally compromised with poor health status and may be cognitively impaired. These factors makes the successful treatment of HIV disease less an issue of the availability of potent pharmacological therapeutics and more dependent on patient ability to adhere to a complex medication regiment over time. However, rigorous methods of measuring adherence to anti-retroviral medication are not widely available and most clinical trials have employed minimal, if any, evaluation of medication adherence. The Medication Adherence Core is validating interview-based methodology to measure adherence based on newly developed items and work done in the ACTG and HCSUS studies. These instruments measure patient adherence to work with HIV clinical trials and cohort studies at UCLA to (1) identify opportunities to measure medication adherence, (2) provide and customize instruments for incorporation into existing and planned studies. (3) assist in design of data collection and analysis strategies to measure adherence and factors associated with adherence, and (4) adapt previously validated instruments for new populations (such as pediatrics) and clinical settings. In addition, the Medication Adherence Core will work with clinical trial investigators to develop interventions to enhance adherence and to measure the effects of these interventions. In addition, with the Behavioral Adherence Recruitment and Retention Core, this Core will create coherent assessment modules of medical and behavioral adherence for UCLA investigators. Both Cores will constitute the Health Behavior and Outreach Program of the CFAR.